SRSTOCK RADAR

Today

July 25, 2026

Today's Alerts

10Last 24H

Dilution Risk

5Last 7D

Listing Risk

37Last 30D

Earnings

9Last 7D

Insider / Ownership

3Last 14D

Dividends

1Last 30D

FDA / Clinical

7Last 30D
Oil & GasIndustry
Policy Regulation
Counter Terrorism Designations; Iran-related Designations

OFAC designated IRGC-linked oil trading, shipping, and front companies, raising sanctions risk for Iran-related oil trade, tankers, and banks.

volatileImpact 72
Power Energy ResourcesTheme
Policy Regulation
Fact Sheet: President Donald J. Trump Secures Historic Deals with China, Delivering for American Workers, Farmers, and Industry

U.S.-China agreements reopen China to Boeing, commit to rare-earth cooperation, and guarantee large agricultural purchases, easing trade and supply-chain tensions.

bullishImpact 80
AI AsicSub Theme
Sales Performance
SEMIFIVE Reports 137% YoY Revenue Growth in Q1 2026, Accelerating Its Rise as a Key Global Player in AI ASIC

SEMIFIVE posts 137% YoY Q1 revenue growth and large mass-production order intake.

bullishImpact 62
Cybersecurity & Network ServicesIndustry
Other
Nexusguard Releases 2025 DDoS Threat Analysis and Industry Perspectives Report

Nexusguard's report warns DDoS attacks grew sharply in 2025, pushing demand for regional, accountability-focused defenses.

bullishImpact 60
Platinum MarketSub Theme
Macro Market
Fourth consecutive platinum market deficit forecast for 2026 - supply to fall short of demand by 297 koz

WPIC forecasts a 297 koz platinum deficit in 2026 and shrinking above-ground stocks to under three months' cover.

bullishImpact 60
Passenger TransitIndustry
Macro Market
3,500 WORKERS WALK OUT AS BLET TEAMSTERS, UNION COALITION LAUNCH LIRR STRIKE

3,500 LIRR union workers struck, halting service for ~300,000 daily riders and disrupting New York commutes.

volatileImpact 65
Pharmaceuticals & BiotechnologyIndustry
Product Update
New Real-World Case Series Examines Re-Induction with ADSTILADRIN® (nadofaragene firadenovec-vncg) in Clinical Practice

Small U.S. real-world case series shows ~31% complete responses after ADSTILADRIN re-induction in BCG‑unresponsive NMIBC.

neutralImpact 55